B of A Securities raises ACADIA price target to $30
B of A Securities analyst Tazeen Ahmad maintained a Buy rating on ACADIA Pharmaceuticals and raised the price target to $30 from $29.

*this image is generated using AI for illustrative purposes only.
B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on ACADIA Pharmaceuticals, raising the price target to $30 from $29. The adjustment reflects an updated outlook on the NASDAQ-listed stock.
Rating and Price Target Details
The revised price target of $30 represents an increase from the previous target of $29. The Buy rating was maintained, indicating continued confidence in the company's performance.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $29 |
| New Price Target | $30 |
What specific factors drove the modest increase in ACADIA's price target?
How might ACADIA's upcoming product pipeline influence its stock performance?
What are the potential risks to ACADIA's growth trajectory in the current market?























